Albert Labs International(VB50)株式概要アルバート・ラボ・インターナショナル社は、バイオ医薬品の創薬企業で、カナダと英国において、緊急かつアンメットニーズのある患者のためのサイケデリック補助療法のための薬剤を研究開発している。 詳細VB50 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析マイナスの株主資本 収益が 100 万ドル未満 ( CA$0 )意味のある時価総額がありません ( €247K )株式の流動性は非常に低い +1 さらなるリスクすべてのリスクチェックを見るVB50 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.005該当なし内在価値ディスカウントEst. Revenue$PastFuture-7m12016201920222025202620282031Revenue CA$1.0Earnings CA$0.2AdvancedSet Fair ValueView all narrativesAlbert Labs International Corp. 競合他社bioXXmedSymbol: DB:T5OMarket cap: €222.9kbioXXmedSymbol: XTRA:T5O0Market cap: €329.8kEpigenomicsSymbol: DB:ECXMarket cap: €763.0kRespiratoriusSymbol: DB:HF00Market cap: €19.4m価格と性能株価の高値、安値、推移の概要Albert Labs International過去の株価現在の株価CA$0.00552週高値CA$0.01652週安値CA$0.0015ベータ3.131ヶ月の変化0%3ヶ月変化0%1年変化-50.00%3年間の変化n/a5年間の変化n/aIPOからの変化-94.44%最新ニュースお知らせ • Oct 19Albert Labs International Corp. Appoints Shabir Hasham to Its Board of DirectorsAlbert Labs International Corp. announced the appointment of Dr. Shabir Hasham to its Board of Directors. With an impressive 20 years of distinguished industry experience, Dr. Hasham brings a wealth of expertise to guide Albert Labs in its mission to revolutionize mental health solutions. Dr. Hasham's exceptional career is marked by his proficiency in navigating regulatory bodies, including the FDA and MHRA, ensuring successful product launches and compliance. His regulatory acumen aligns seamlessly with Albert Labs' commitment to delivering innovative mental health solutions. As the former EU Medical Director for the Neuroscience Franchise at Novartis, Dr. Hasham played a pivotal role in advancing pharmaceutical solutions. His leadership is a testament to his deep understanding of the complexities involved in bringing transformative medicines to market. Dr. Shabir Hasham's arrival marks a reunion with former team members, including Chief Medical Officer Dr. Malcolm Barrett Johnson and Chief Operations Officer Santoke Naal. His past collaborations with these key individuals, particularly during their tenure at Novartis, underscore Dr. Hasham's exceptional ability to drive successful outcomes in a collaborative environment. In addition to his 20 years of experience, Dr. Shabir Hasham will be progressively taking on an increased leadership role within Albert Labs. His informal leadership style, combined with strategic planning and operational excellence, aligns seamlessly with the company's vision for transformative solutions in mental health pharmaceuticals. Dr. Hasham possesses a unique proficiency in dealing with biotechnology and healthcare investment funds. His strategic insights have effectively guided investments, contributing to the success of various projects. Dr. Hasham's ability to communicate complex ideas in the right manner has been instrumental in securing support from investment entities, and ensuring alignment with organizational goals. Albert Labs looks forward to leveraging Dr. Shabir Hasham's multifaceted expertise as the company continues its pursuit of excellence in mental health pharmaceuticals.Board Change • Sep 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 07Albert Labs International Corp. Announces CEO ChangesAlbert Labs Management and Board of Director Announcement Effective immediately, Michael Raymont has resigned from his position of chief executive officer and director of Albert Labs International Corp., and Mike Thompson has resigned from the board of directors. The board of directors extends its sincerest gratitude to Mr. Raymont and Mr. Thompson for their contributions to the company. Chand Jagpal will be acting as the interim chief executive officer until a suitable candidate is found.お知らせ • Sep 06Albert Labs International Corp. Announces Resignation of Michael Raymont as Board of DirectorsAlbert Labs Management and Board of Director Announcement Effective immediately, Michael Raymont has resigned from his position of chief executive officer and director of Albert Labs International Corp., and Mike Thompson has resigned from the board of directors. The board of directors extends its sincerest gratitude to Mr. Raymont and Mr. Thompson for their contributions to the company. Chand Jagpal will be acting as the interim chief executive officer until a suitable candidate is found.Board Change • Aug 14No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jul 11No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.最新情報をもっと見るRecent updatesお知らせ • Oct 19Albert Labs International Corp. Appoints Shabir Hasham to Its Board of DirectorsAlbert Labs International Corp. announced the appointment of Dr. Shabir Hasham to its Board of Directors. With an impressive 20 years of distinguished industry experience, Dr. Hasham brings a wealth of expertise to guide Albert Labs in its mission to revolutionize mental health solutions. Dr. Hasham's exceptional career is marked by his proficiency in navigating regulatory bodies, including the FDA and MHRA, ensuring successful product launches and compliance. His regulatory acumen aligns seamlessly with Albert Labs' commitment to delivering innovative mental health solutions. As the former EU Medical Director for the Neuroscience Franchise at Novartis, Dr. Hasham played a pivotal role in advancing pharmaceutical solutions. His leadership is a testament to his deep understanding of the complexities involved in bringing transformative medicines to market. Dr. Shabir Hasham's arrival marks a reunion with former team members, including Chief Medical Officer Dr. Malcolm Barrett Johnson and Chief Operations Officer Santoke Naal. His past collaborations with these key individuals, particularly during their tenure at Novartis, underscore Dr. Hasham's exceptional ability to drive successful outcomes in a collaborative environment. In addition to his 20 years of experience, Dr. Shabir Hasham will be progressively taking on an increased leadership role within Albert Labs. His informal leadership style, combined with strategic planning and operational excellence, aligns seamlessly with the company's vision for transformative solutions in mental health pharmaceuticals. Dr. Hasham possesses a unique proficiency in dealing with biotechnology and healthcare investment funds. His strategic insights have effectively guided investments, contributing to the success of various projects. Dr. Hasham's ability to communicate complex ideas in the right manner has been instrumental in securing support from investment entities, and ensuring alignment with organizational goals. Albert Labs looks forward to leveraging Dr. Shabir Hasham's multifaceted expertise as the company continues its pursuit of excellence in mental health pharmaceuticals.Board Change • Sep 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 07Albert Labs International Corp. Announces CEO ChangesAlbert Labs Management and Board of Director Announcement Effective immediately, Michael Raymont has resigned from his position of chief executive officer and director of Albert Labs International Corp., and Mike Thompson has resigned from the board of directors. The board of directors extends its sincerest gratitude to Mr. Raymont and Mr. Thompson for their contributions to the company. Chand Jagpal will be acting as the interim chief executive officer until a suitable candidate is found.お知らせ • Sep 06Albert Labs International Corp. Announces Resignation of Michael Raymont as Board of DirectorsAlbert Labs Management and Board of Director Announcement Effective immediately, Michael Raymont has resigned from his position of chief executive officer and director of Albert Labs International Corp., and Mike Thompson has resigned from the board of directors. The board of directors extends its sincerest gratitude to Mr. Raymont and Mr. Thompson for their contributions to the company. Chand Jagpal will be acting as the interim chief executive officer until a suitable candidate is found.Board Change • Aug 14No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jul 11No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 01No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.株主還元VB50DE BiotechsDE 市場7D0%0.8%-1.7%1Y-50.0%-7.6%-0.6%株主還元を見る業界別リターン: VB50過去 1 年間で-7.6 % の収益を上げたGerman Biotechs業界を下回りました。リターン対市場: VB50は、過去 1 年間で-0.6 % のリターンを上げたGerman市場を下回りました。価格変動Is VB50's price volatile compared to industry and market?VB50 volatilityVB50 Average Weekly Movementn/aBiotechs Industry Average Movement8.4%Market Average Movement5.7%10% most volatile stocks in DE Market13.4%10% least volatile stocks in DE Market2.8%安定した株価: VB50の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のVB50のボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO(最高経営責任者ウェブサイトn/an/aChand Jagpalalbertlabs.comアルバート・ラボ・インターナショナル社は、バイオ医薬品の創薬企業であり、カナダと英国において、緊急かつアンメットニーズのある患者のためのサイケデリック補助療法のための薬剤を研究開発している。同社が開発したKRN-101は、がんに関連した不安の解決薬である。本社はカナダのバーナビー。もっと見るAlbert Labs International Corp. 基礎のまとめAlbert Labs International の収益と売上を時価総額と比較するとどうか。VB50 基礎統計学時価総額€247.24k収益(TTM)-€1.53m売上高(TTM)n/a0.0xP/Sレシオ-0.2xPER(株価収益率VB50 は割高か?公正価値と評価分析を参照収益と収入最新の決算報告書(TTM)に基づく主な収益性統計VB50 損益計算書(TTM)収益CA$0売上原価CA$0売上総利益CA$0その他の費用CA$2.31m収益-CA$2.31m直近の収益報告Sep 30, 2023次回決算日該当なし一株当たり利益(EPS)-0.031グロス・マージン0.00%純利益率0.00%有利子負債/自己資本比率-2.3%VB50 の長期的なパフォーマンスは?過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2024/10/13 03:46終値2024/07/16 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Albert Labs International Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Oct 19Albert Labs International Corp. Appoints Shabir Hasham to Its Board of DirectorsAlbert Labs International Corp. announced the appointment of Dr. Shabir Hasham to its Board of Directors. With an impressive 20 years of distinguished industry experience, Dr. Hasham brings a wealth of expertise to guide Albert Labs in its mission to revolutionize mental health solutions. Dr. Hasham's exceptional career is marked by his proficiency in navigating regulatory bodies, including the FDA and MHRA, ensuring successful product launches and compliance. His regulatory acumen aligns seamlessly with Albert Labs' commitment to delivering innovative mental health solutions. As the former EU Medical Director for the Neuroscience Franchise at Novartis, Dr. Hasham played a pivotal role in advancing pharmaceutical solutions. His leadership is a testament to his deep understanding of the complexities involved in bringing transformative medicines to market. Dr. Shabir Hasham's arrival marks a reunion with former team members, including Chief Medical Officer Dr. Malcolm Barrett Johnson and Chief Operations Officer Santoke Naal. His past collaborations with these key individuals, particularly during their tenure at Novartis, underscore Dr. Hasham's exceptional ability to drive successful outcomes in a collaborative environment. In addition to his 20 years of experience, Dr. Shabir Hasham will be progressively taking on an increased leadership role within Albert Labs. His informal leadership style, combined with strategic planning and operational excellence, aligns seamlessly with the company's vision for transformative solutions in mental health pharmaceuticals. Dr. Hasham possesses a unique proficiency in dealing with biotechnology and healthcare investment funds. His strategic insights have effectively guided investments, contributing to the success of various projects. Dr. Hasham's ability to communicate complex ideas in the right manner has been instrumental in securing support from investment entities, and ensuring alignment with organizational goals. Albert Labs looks forward to leveraging Dr. Shabir Hasham's multifaceted expertise as the company continues its pursuit of excellence in mental health pharmaceuticals.
Board Change • Sep 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 07Albert Labs International Corp. Announces CEO ChangesAlbert Labs Management and Board of Director Announcement Effective immediately, Michael Raymont has resigned from his position of chief executive officer and director of Albert Labs International Corp., and Mike Thompson has resigned from the board of directors. The board of directors extends its sincerest gratitude to Mr. Raymont and Mr. Thompson for their contributions to the company. Chand Jagpal will be acting as the interim chief executive officer until a suitable candidate is found.
お知らせ • Sep 06Albert Labs International Corp. Announces Resignation of Michael Raymont as Board of DirectorsAlbert Labs Management and Board of Director Announcement Effective immediately, Michael Raymont has resigned from his position of chief executive officer and director of Albert Labs International Corp., and Mike Thompson has resigned from the board of directors. The board of directors extends its sincerest gratitude to Mr. Raymont and Mr. Thompson for their contributions to the company. Chand Jagpal will be acting as the interim chief executive officer until a suitable candidate is found.
Board Change • Aug 14No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jul 11No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 19Albert Labs International Corp. Appoints Shabir Hasham to Its Board of DirectorsAlbert Labs International Corp. announced the appointment of Dr. Shabir Hasham to its Board of Directors. With an impressive 20 years of distinguished industry experience, Dr. Hasham brings a wealth of expertise to guide Albert Labs in its mission to revolutionize mental health solutions. Dr. Hasham's exceptional career is marked by his proficiency in navigating regulatory bodies, including the FDA and MHRA, ensuring successful product launches and compliance. His regulatory acumen aligns seamlessly with Albert Labs' commitment to delivering innovative mental health solutions. As the former EU Medical Director for the Neuroscience Franchise at Novartis, Dr. Hasham played a pivotal role in advancing pharmaceutical solutions. His leadership is a testament to his deep understanding of the complexities involved in bringing transformative medicines to market. Dr. Shabir Hasham's arrival marks a reunion with former team members, including Chief Medical Officer Dr. Malcolm Barrett Johnson and Chief Operations Officer Santoke Naal. His past collaborations with these key individuals, particularly during their tenure at Novartis, underscore Dr. Hasham's exceptional ability to drive successful outcomes in a collaborative environment. In addition to his 20 years of experience, Dr. Shabir Hasham will be progressively taking on an increased leadership role within Albert Labs. His informal leadership style, combined with strategic planning and operational excellence, aligns seamlessly with the company's vision for transformative solutions in mental health pharmaceuticals. Dr. Hasham possesses a unique proficiency in dealing with biotechnology and healthcare investment funds. His strategic insights have effectively guided investments, contributing to the success of various projects. Dr. Hasham's ability to communicate complex ideas in the right manner has been instrumental in securing support from investment entities, and ensuring alignment with organizational goals. Albert Labs looks forward to leveraging Dr. Shabir Hasham's multifaceted expertise as the company continues its pursuit of excellence in mental health pharmaceuticals.
Board Change • Sep 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 07Albert Labs International Corp. Announces CEO ChangesAlbert Labs Management and Board of Director Announcement Effective immediately, Michael Raymont has resigned from his position of chief executive officer and director of Albert Labs International Corp., and Mike Thompson has resigned from the board of directors. The board of directors extends its sincerest gratitude to Mr. Raymont and Mr. Thompson for their contributions to the company. Chand Jagpal will be acting as the interim chief executive officer until a suitable candidate is found.
お知らせ • Sep 06Albert Labs International Corp. Announces Resignation of Michael Raymont as Board of DirectorsAlbert Labs Management and Board of Director Announcement Effective immediately, Michael Raymont has resigned from his position of chief executive officer and director of Albert Labs International Corp., and Mike Thompson has resigned from the board of directors. The board of directors extends its sincerest gratitude to Mr. Raymont and Mr. Thompson for their contributions to the company. Chand Jagpal will be acting as the interim chief executive officer until a suitable candidate is found.
Board Change • Aug 14No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jul 11No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 01No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.